• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect Public Health . Severe COVID-19 pneumonia in Piacenza, Italy - A cohort study of the first pandemic wave

tetano

Editor, Senior Moderator
J Infect Public Health


. 2020 Dec 9;14(2):263-270.
doi: 10.1016/j.jiph.2020.11.012. Online ahead of print.
Severe COVID-19 pneumonia in Piacenza, Italy - A cohort study of the first pandemic wave


Lorenzo Guglielmetti[SUP] 1 [/SUP], Irina Kontsevaya[SUP] 2 [/SUP], Maria C Leoni[SUP] 3 [/SUP], Patrizia Ferrante[SUP] 4 [/SUP], Elisa Fronti[SUP] 5 [/SUP], Laura Gerna[SUP] 6 [/SUP], Caterina Valdatta[SUP] 7 [/SUP], Alessandra Donisi[SUP] 8 [/SUP], Alberto Faggi[SUP] 9 [/SUP], Franco Paolillo[SUP] 10 [/SUP], Giovanna Ratti[SUP] 11 [/SUP], Alessandro Ruggieri[SUP] 12 [/SUP], Marta Scotti[SUP] 13 [/SUP], Daria Sacchini[SUP] 14 [/SUP], Gloria Taliani[SUP] 15 [/SUP], Mauro Codeluppi[SUP] 16 [/SUP], COVID-Piacenza Group



Affiliations

Abstract

Background: Piacenza is the closest city to the first coronavirus disease 2019 (COVID-19) cluster in Italy and has the highest national COVID-19 death rates per population. The objective of this study is to present characteristics and outcomes of patients admitted to medical departments of the Hospital of Piacenza during the first wave of the epidemic.
Methods: A total of 218 patients with confirmed or suspect COVID-19 and severe pneumonia were included from February 21st to May 15th, 2020. Routinely-collected clinical and laboratory data were retrospectively retrieved from electronic medical files. A Cox proportional-hazards model was fit to assess the association of treatment and other variables with death.
Results: Median age of patients was 68 years; 150 patients (69%) had comorbidities, mainly hypertension (107, 49%). Overall, 185 (85%) patients had acute respiratory distress syndrome (ARDS) on admission, including 103 (47%) with moderate or severe ARDS. Chest computed tomography scan showed bilateral disease in 201 (98%) and extensive lung involvement in 79 (50%) patients. Most patients received antiviral treatment (187, 86%) and corticosteroids (134, 61%). All patients received respiratory support and 64 (29%) were admitted to intensive care unit. As of June 30th, 100 patients (46%) died, 109 patients (50%) were discharged, and 9 patients (4%) were still hospitalized. In multivariable Cox analysis, age above 65 years, having more than one comorbidity, severe ARDS, low platelet counts, and high LDH levels at admission were associated with mortality, while having diarrhea at admission was associated with survival. The use of antivirals or corticosteroids was not associated with survival.
Conclusions: Overall case fatality rates were high and associated with comorbidities, extensive lung involvement, ARDS at admission, and advanced age. The use of antivirals was not associated with increased survival.

Keywords: Acute respiratory distress syndrome; Coronavirus; Mortality; SARS-CoV-2; Viral pneumonia.
 
Back
Top Bottom